SON Stock Recent News

Sonoco's (SON) Q2 top line reflects the impacts of the divestiture of Protective Solutions and the thermoformed food packaging plant closure.

Sonoco Products Company (NYSE:SON ) Q2 2024 Results Conference Call August 1, 2024 9:30 AM ET Company Participants Lisa Weeks - VP of Investor Relations & Corporate Affairs Howard Coker - President, CEO & Director Rob Dillard - Chief Financial Officer Rodger Fuller - Chief Operating Officer Conference Call Participants Matt Roberts - Raymond James George Staphos - BofA Ghansham Panjabi - Baird Mark Weintraub - Seaport Research Partners Gregory Andreopoulos - Citi Operator Good day, and thank you for standing by. Welcome to the Q2 2024 Sonoco Earnings Conference Call.

Sonoco (SON) came out with quarterly earnings of $1.28 per share, beating the Zacks Consensus Estimate of $1.26 per share. This compares to earnings of $1.38 per share a year ago.

HARTSVILLE, S.C., July 31, 2024 (GLOBE NEWSWIRE) -- Sonoco Products Company (“Sonoco” or the “Company”) (NYSE: SON), one of the largest sustainable global packaging companies, today reported financial results for its second quarter ended June 30, 2024.

HARTSVILLE, S.C.--(BUSINESS WIRE)--Today, Paired Power, a leading U.S. solar microgrid electric vehicle charger manufacturer announces its installation of its PairTree EV charger for Sonoco (NYSE: SON), a leading global manufacturer of consumer, industrial, health care and protective packaging. “We're thrilled to provide the first offgrid electric vehicle solar charger to Sonoco, a world-class company with a strong track record of reducing emissions through recyclable material sourcing and coun.

HARTSVLLE, S.C., July 24, 2024 (GLOBE NEWSWIRE) -- Sonoco Products Company (“Sonoco” or the “Company”)(NYSE: SON), one of the largest global sustainable packaging companies, will announce second quarter 2024 results on Wednesday, July 31, 2024 after the market closes.

PRINCETON, N.J., July 24, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (the “Company” or “Sonnet”) (NASDAQ:SONN), a clinical-stage company developing targeted immunotherapeutic drugs, today announced encouraging data from the Phase 1b portion of its Phase 1b/2a clinical trial evaluating SON-080 for the treatment of CIPN (the “SB211 study”). The SB211 study is a double-blind, randomized, controlled trial of SON-080 conducted at two sites in Australia in patients with persistent CIPN using a new proprietary version of recombinant human Interleukin-6 (rhIL-6) that builds upon previous work with atexakin alfa. The goal of the Phase 1b portion of the SB211 study was to confirm safety and tolerability before continued development in Phase 2. As previously announced in March 2024, a data and safety monitoring board reviewed the unblinded safety and tolerability of SON-080 in the first nine patients and concluded that the symptoms were tolerable in the initial pat

Sonoco (SON) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

HARTSVILLE, S.C., July 17, 2024 (GLOBE NEWSWIRE) -- The Board of Directors of Sonoco (NYSE: SON) has declared a $0.52 per share quarterly common stock dividend.

Sonoco Products Company's shares have come under pressure after a big acquisition, as a poor share price reaction prices-in a lot of bad news. The company has a long heritage, being founded in 1899, and has a great long-term dividend track record. The recently announced acquisition of Eviosys is expected to drive immediate earnings accretion and synergies, but leverage ratios are a concern.